Cargando…
Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
The optimal antiviral regimen for hepatitis C virus (HCV) genotype 4 is still a subject of investigation. The report in this issue of Health Science Reports by Asselah and colleagues investigated the additional benefit of extending treatment duration of the ombitasvir/paritaprevir/ritonavir plus rib...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427055/ https://www.ncbi.nlm.nih.gov/pubmed/30937390 http://dx.doi.org/10.1002/hsr2.106 |